Protein tyrosine phosphatase 1B inhibitors for diabetes
- 1 September 2002
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Drug Discovery
- Vol. 1 (9), 696-709
- https://doi.org/10.1038/nrd895
Abstract
Increased incidence of type 2 diabetes mellitus and obesity has elevated the medical need for new agents to treat these disease states. Resistance to the hormones insulin and leptin are hallmarks of both type 2 diabetes and obesity. Drugs that can ameliorate this resistance should be effective in treating type 2 diabetes and possibly obesity. Protein tyrosine phosphatase 1B (PTP1B) is thought to function as a negative regulator of insulin and leptin signal transduction. This article reviews PTP1B as a novel target for type 2 diabetes, and looks at the challenges in developing small-molecule inhibitors of this phosphatase.Keywords
This publication has 83 references indexed in Scilit:
- Interaction of protein tyrosine phosphatase (PTP) 1B with its substrates is influenced by two distinct binding domainsBiochemical Journal, 2002
- Decreasing hypothalamic insulin receptors causes hyperphagia and insulin resistance in ratsNature Neuroscience, 2002
- Protein Tyrosine Phosphatase 1BDevelopmental Cell, 2002
- Childhood Obesity and a Diabetes EpidemicNew England Journal of Medicine, 2002
- A Pit Stop at the ERScience, 2002
- Insulin signalling and the regulation of glucose and lipid metabolismNature, 2001
- Global and societal implications of the diabetes epidemicNature, 2001
- Murine embryonic fibroblasts lacking TC-PTP display delayed G1 phase through defective NF-κB activationOncogene, 2001
- Protein-tyrosine Phosphatase-1B Negatively Regulates Insulin Signaling in L6 Myocytes and Fao Hepatoma CellsPublished by Elsevier BV ,2001
- Potent Inhibition of Insulin Receptor Dephosphorylation by a Hexamer Peptide Containing the Phosphotyrosyl Mimetic F2PmpBiochemical and Biophysical Research Communications, 1994